Guerin Mark Patrick
Known title: CFO AND COOCIK: 0001607714
Associated companies
Transaction History
| TRAW | ▼ Sell | Tax Withholding | 2,221 | $1K | 6/18/2024 | View on chart |
| TRAW | ▲ Buy | Option Exercise | 5,500 | — | 6/10/2024 | View on chart |
| TRAW | ▼ Sell | Tax Withholding | 2,591 | $2K | 3/14/2024 | View on chart |
| TRAW | ▲ Buy | Option Exercise | 8,666 | — | 3/13/2024 | View on chart |
| TRAW | ▲ Buy | Option Exercise | 6,900 | — | 2/7/2024 | View on chart |
| TRAW | ▼ Sell | Tax Withholding | 2,443 | $2K | 2/7/2024 | View on chart |
| TRAW | ▼ Sell | Tax Withholding | 1,422 | $1K | 8/3/2023 | View on chart |
| TRAW | ▲ Buy | Option Exercise | 4,750 | — | 8/2/2023 | View on chart |
| TRAW | ▲ Buy | Option Exercise | 5,500 | — | 6/12/2023 | View on chart |
| TRAW | ▼ Sell | Tax Withholding | 1,575 | $2K | 6/12/2023 | View on chart |
| TRAW | ▲ Buy | Option Exercise | 6,900 | — | 2/7/2023 | View on chart |
| TRAW | ▼ Sell | Tax Withholding | 1,785 | $2K | 2/7/2023 | View on chart |
| TRAW | ▼ Sell | Tax Withholding | 1,355 | $2K | 8/3/2022 | View on chart |
| TRAW | ▲ Buy | Option Exercise | 4,750 | — | 8/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Traws Pharma listed in Benzinga health care movers
Traws Pharma was included in Benzinga's recent lists of health care stocks moving in pre-market and after-market sessions. These mentions indicate that the stock experienced price volatility relative to its peers during those trading periods. The company's shares currently trade near the middle of their 52-week range, with an average analyst target of $1.00.
Traws Pharma listed in Benzinga health care movers. Traws Pharma was included in Benzinga's recent lists of health care stocks moving in pre-market and after-market sessions. These mentions indicate that the stock experienced price volatility relative to its peers during those trading periods. The company's shares currently trade near the middle of their 52-week range, with an average analyst target of $1.00.